Stay updated on Fenebrutinib vs Ocrelizumab in Primary Progressive MS Clinical Trial
Sign up to get notified when there's something new on the Fenebrutinib vs Ocrelizumab in Primary Progressive MS Clinical Trial page.

Latest updates to the Fenebrutinib vs Ocrelizumab in Primary Progressive MS Clinical Trial page
- Check4 days agoChange Detected403 Forbidden error page is shown instead of the study content. This indicates restricted access to the study record rather than displaying its details.SummaryDifference17%

- Check11 days agoChange DetectedThe page's revision marker updated from v3.6.6 to v3.7.0, indicating a minor update to the page version.SummaryDifference0.0%

- Check19 days agoChange DetectedThe Belo Horizonte recruitment site is updated to Freire Pesquisa Clinica at 30150-320, replacing the previous listing at 30150-221 (Santa Casa de Misericordia). The study arms are clarified to include fenebrutinib with an ocrelizumab-matching placebo and vice versa, and Time to Onset of Composite 12-Week Confirmed Disability Progression (cCDP12) is added as an outcome, along with related administrative Certification/Extension entries.SummaryDifference0.3%

- Check26 days agoChange DetectedThe page's revision label was updated to v3.6.6, replacing the previous v3.6.5. This indicates a backend page update rather than a change to the study details or functionality.SummaryDifference0.0%

- Check33 days agoChange DetectedThe study record now includes a funding attribution: 2019 ( U.S. NIH Grant/Contract ), clarifying the source of support for the research.SummaryDifference0.0%

- Check47 days agoChange DetectedA revision update is shown, changing the version from v3.6.4 to v3.6.5, indicating a small behind-the-scenes update rather than any visible content or feature changes.SummaryDifference0.0%

Stay in the know with updates to Fenebrutinib vs Ocrelizumab in Primary Progressive MS Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Fenebrutinib vs Ocrelizumab in Primary Progressive MS Clinical Trial page.